Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Preferred Stock Liabilities (2019)

Vivos Therapeutics (VVOS) has disclosed Preferred Stock Liabilities for 1 consecutive years, with $1.3 million as the latest value for Q4 2019.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $1.3 million in Q4 2019 year-over-year; TTM through Dec 2019 was $1.3 million, a N/A change, with the full-year FY2019 number at $1.3 million, changed N/A from a year prior.
  • Preferred Stock Liabilities was $1.3 million for Q4 2019 at Vivos Therapeutics.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $1.3 million in Q4 2019 to a low of $1.3 million in Q4 2019.